Abstract
• Within the last year, several therapeutic strategies have been shown to improve survival outcomes in patients with localized or metastatic TNBC . • Newly approved agents include pembrolizumab , olaparib , and sacituzumab govitecan . • The approval of these treatments raises several questions regarding optimizing the clinical application of the new options.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
